Collaboration with the College of Birmingham to start out the primary medical trial in myocardial infarction

Photo credits © Acticor Biotech

( – Following the signing of a partnership between the University of Birmingham and Actor Biotecha new clinical trial called LIBERATE is being conducted in two acute care hospitals in the UK: Queen Elizabeth Hospital, Birmingham and Northern General Hospital, Sheffield.

The Phase 2b, randomized, double-blind LIBERATE study is enrolling more than 200 patients to evaluate the safety and efficacy of glenzocimab 1,000 mg versus placebo in reducing heart damage after myocardial infarction (MI), commonly known as heart attack.

The study is being conducted at the University of Birmingham with experienced clinicians from the Institute of Cardiovascular Sciences and the University Hospitals Birmingham NHS Foundation Trust. Using the CTU’s (Clinical Trial Units) experience in conducting multi-centre clinical trials and their expertise in heart disease, the team will test whether glenzocimab reduces the amount of damaged heart tissue in patients undergoing ST-segment elevation myocardial infarction (STEMI). have suffered the most severe type of heart attack.

Professor Jon Townend, Consultant Cardiologist at Birmingham University Hospitals, Honorary Professor of Cardiology at the University of Birmingham Institute of Cardiovascular Sciences and Principal Investigator on the study, said: “We look forward to initiating this study with this new drug as there is still a long way to go pathology is common. Although coronary angioplasty has become routine, there are still sequelae. Glenzocimab reduces thrombosis and the laboratory results are impressive. There are important reasons to believe that glenzocimab can improve these outcomes and this study is the best way to demonstrate that.”

dr Mark Thomas, Associate Professor of Cardiology at the University of Birmingham and Honorary Consultant Cardiologist who designed the study and led its development, said: “This study will help us determine whether glenzocimab is a safe and effective drug to reduce the risk of secondary disease prevent thrombosis, which can lead to serious heart damage after a heart attack. We are excited to be working with Acticor to see if this new class of drugs has the potential to improve outcomes for our patients who are victims of a heart attack effectively improves patient survival, we could do more to prevent long-term consequences.”

Glenzocimab, a humanized monoclonal antibody (Fab) fragment directed against platelet glycoprotein VI (GPVI), was developed by Acticor Biotech for the treatment of cardiovascular emergencies, including stroke. This new drug is currently being tested in the treatment of stroke and has shown excellent tolerability and a reduction in cerebral hemorrhage and mortality when added to standard care.


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button